clinical trial · NCT03501368
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
H. Lee Moffitt Cancer Center and Research Institute·phase1·completed·n = 27
MelanomaUnresectable MelanomaAdvanced MelanomaCeritinibTrametinib
brief summary
The main purpose of this study is to determine the risks and benefits of ceritinib (ZYKADIA) given in combination with trametinib (MEKINIST) in patients who have progressed on prior melanoma therapy.
started
Jun 27, 2018
primary completion
Oct 28, 2022
completion
Dec 30, 2024
last updated
Feb 27, 2026
detailed description
Ceritinib that has been approved for patients with metastatic non-small cell lung cancer (NSCLC) by the US Food and Drug Administration (FDA). While ceritinib is not currently FDA-approved specifically in melanoma, researchers believe ceritinib may also help keep melanoma cancer cells from growing and therefore potentially help patients with melanoma as well. Trametinib is currently FDA-approved for melanoma with a BRAFV600-mutation.
official title
Phase 1 Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol